Bolt Biotherapeutics, Inc. (NasdaqCM: BOLT)
Health Care · Biotechnology · US
$3.92
+6.96% today · -32.7% 1Y
Bolt Biotherapeutics, Inc. (NasdaqCM: BOLT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $7.06M and employs 23 people.
Over the last twelve months the share price has lost 32.7%, trading between 3.13 and 7.20.
Tweenvest scores Bolt Biotherapeutics, Inc. across four factors: quality 16/100, value 62/100, growth 83/100. Its strongest factor is growth.
BOLT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $7.06M
- Revenue (TTM)
- $4.70M
- P/E
- —
- EPS
- -16.38
- Dividend yield
- —
- Beta (5Y)
- 1.08
- 52-week high
- $7.20
- 52-week low
- $3.13
- Avg volume (3M)
- —
- Shares outstanding
- 1.93M
- Employees
- 23
- Next earnings
- —
About Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. is a biotechnology company currently conducting clinical trials, focused on developing innovative immuno-oncology therapies. Its mission is to create agents that equip the body's immune system to identify and eliminate cancerous cells. A key therapeutic in its pipeline is BDC-1001, an investigational treatment targeting the human epidermal growth factor receptor 2 (HER2). This compound is presently undergoing Phase I/II clinical evaluation for patients with HER2-positive solid tumors, including those exhibiting low HER2 expression. Beyond BDC-1001, the company is advancing several other programs: BDC-2034, which targets carcinoembryonic antigen for various indications such as colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody designed to reprogram crucial immune cells within the tumor microenvironment by interacting with macrophage cell-surface receptors. Bolt is also pursuing a programmed cell death-ligand 1 (PD-L1) initiative aimed at addressing tumors that prove resistant to existing immune checkpoint blockades. Incorporated in 2015 under its previous name, Bolt Therapeutics, Inc., before officially becoming Bolt Biotherapeutics, Inc. in July of the same year, the company maintains its corporate headquarters in Redwood City, California.
- ISIN
- US0977022039
- Founded
- 2015
- Listed since
- Feb 5, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $262.90 | -1.09% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $440.34 | -0.43% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.09 | -0.46% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $547.29 | -1.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $814.79 | -2.25% |
| argenx SEENXTBR: ARGX | $64.17B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $149.66 | -5.77% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.